Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 295 participants.
Also called NCT03715998
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 295 participants
- Sponsor
- Registry
-
NCT03715998
-
- Other papers using this trial's data
- Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- France, Germany, Hungary, Poland, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03715998. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-04 (actual); primary completion 2021-07-08 (actual). Results posted on 2023-02-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
- Acronym
- QUORUM
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Ramipril
- Intervention (Drug)
- Firibastat
- Lead sponsor
- Quantum Genomics SA
Record details
- Record id
cardio:ct-nct03715998- Content hash
91b2903fcf474a456922bc080a540f71c89192cb12b52e0c00c596325c38e1fd